JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY

Scope & Guideline

Bridging research and practice in pediatric mental health.

Introduction

Explore the comprehensive scope of JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY through our detailed guidelines, including its aims and scope. Stay updated with trending and emerging topics, and delve into declining areas to understand shifts in academic interest. Our guidelines also showcase highly cited topics, featuring influential research making a significant impact. Additionally, discover the latest published papers and those with high citation counts, offering a snapshot of current scholarly conversations. Use these guidelines to explore JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY in depth and align your research initiatives with current academic trends.
LanguageEnglish
ISSN1044-5463
PublisherMARY ANN LIEBERT, INC
Support Open AccessNo
CountryUnited States
TypeJournal
Convergefrom 1990 to 2024
AbbreviationJ CHILD ADOL PSYCHOP / J. Child Adolesc. Psychopharmacol.
Frequency10 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801

Aims and Scopes

The Journal of Child and Adolescent Psychopharmacology focuses on the intersection of pharmacology and mental health in youth, emphasizing evidence-based practices and innovative treatment approaches. It serves as a platform for sharing research on the efficacy, safety, and psychosocial implications of psychopharmacological interventions in children and adolescents.
  1. Pharmacological Treatment of Psychiatric Disorders:
    The journal extensively covers research related to pharmacological interventions for various psychiatric conditions such as ADHD, depression, anxiety, and psychotic disorders in children and adolescents.
  2. Systematic Reviews and Meta-Analyses:
    A significant portion of publications includes systematic reviews and meta-analyses that aggregate findings from multiple studies to provide comprehensive insights into treatment efficacy and safety.
  3. Innovations in Psychopharmacology:
    The journal highlights cutting-edge research, including novel medications and treatment protocols, contributing to the advancement of psychopharmacology in pediatric populations.
  4. Longitudinal and Cohort Studies:
    Research often employs longitudinal and cohort study designs to assess the long-term effects of psychotropic medications and their impact on developmental outcomes.
  5. Pharmacogenomics and Personalized Medicine:
    The journal increasingly focuses on pharmacogenetic studies that explore genetic factors influencing medication response, aiming to enhance personalized treatment approaches for youth.
  6. Behavioral and Psychosocial Interventions:
    In addition to pharmacological studies, the journal includes research on the integration of behavioral therapies with pharmacological treatments to optimize outcomes in youth.
The Journal of Child and Adolescent Psychopharmacology is witnessing notable trends and emerging themes that reflect the evolving landscape of pediatric mental health research. These themes highlight the journal's responsiveness to contemporary issues in child and adolescent psychiatry.
  1. Innovative Treatment Modalities:
    There is a growing emphasis on exploring new treatment modalities, including the use of ketamine and transcranial magnetic stimulation for treatment-resistant depression, indicating a shift towards more innovative approaches in psychopharmacology.
  2. Pharmacogenetics and Personalized Medicine:
    Recent publications increasingly focus on pharmacogenetic factors that influence medication efficacy and safety, marking a significant trend towards personalized medicine in pediatric psychopharmacology.
  3. Impact of COVID-19 on Youth Mental Health:
    The journal has seen a rise in studies investigating the psychological impact of the COVID-19 pandemic on children and adolescents, emphasizing the need to address emerging mental health challenges.
  4. Metabolic Monitoring in Psychotropic Treatment:
    Research on metabolic monitoring in youth prescribed second-generation antipsychotics is becoming more prevalent, reflecting concerns about long-term health outcomes and the need for comprehensive care.
  5. Intersection of Mental Health and Developmental Disorders:
    There is an increasing trend in exploring the intersectionality of mental health issues with developmental disorders such as autism, highlighting the complexities of treatment in these populations.

Declining or Waning

While the journal continues to explore a wide array of topics in child and adolescent psychopharmacology, certain themes appear to be waning in prominence. This decline may reflect shifting research priorities or advancements in treatment methodologies.
  1. Traditional Antidepressant Studies:
    Research focusing solely on traditional antidepressants, particularly SSRIs without considering adjunct therapies or novel treatments, has decreased as newer modalities gain attention.
  2. Generalized Anxiety Disorder (GAD) Focus:
    While anxiety disorders remain a topic of interest, specific studies centered on GAD alone are less frequent, possibly as a result of a broader focus on anxiety as part of a spectrum of disorders.
  3. Pharmacotherapy for ADHD without Behavioral Interventions:
    There is a noticeable decline in studies examining pharmacotherapy for ADHD in isolation, with a growing emphasis on combined treatment approaches that integrate behavioral interventions.
  4. Longitudinal Studies on Medication Side Effects:
    The frequency of studies specifically focusing on long-term side effects of established medications is decreasing, potentially due to a shift towards understanding efficacy in broader treatment contexts.

Similar Journals

INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY

Advancing the Science of Psychopharmacology
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 0268-1315Frequency: 6 issues/year

INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, published by Lippincott Williams & Wilkins, stands as a pivotal peer-reviewed journal in the fields of pharmacology and psychiatry. Established in 1986, it has garnered a prominent reputation with a 2023 impact factor placing it in the Q2 category for both Pharmacology and Psychiatry and Mental Health. With an impressive Scopus ranking of #227 in the Psychiatry and Mental Health category and #114 in Pharmacology, it serves as an essential platform for researchers seeking to disseminate critical findings on psychopharmacological interventions and their clinical efficacy. The journal’s rigorous peer-review process ensures that only high-quality research is published, making it a trusted resource for professionals and students alike. By focusing on the latest advancements and evidence-based practices, the INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY contributes significantly to the understanding of mental health treatments, fostering ongoing dialogue and innovation in the discipline.

EXPERIMENTAL AND CLINICAL PSYCHOPHARMACOLOGY

Advancing the Science of Psychopharmacology
Publisher: AMER PSYCHOLOGICAL ASSOCISSN: 1064-1297Frequency: 6 issues/year

EXPERIMENTAL AND CLINICAL PSYCHOPHARMACOLOGY, published by the American Psychological Association, stands as a pivotal resource within the fields of pharmacology and psychiatry. With an ISSN of 1064-1297 and an E-ISSN of 1936-2293, this journal contributes significantly to the understanding of psychopharmacological interventions through its rich array of research articles, reviews, and clinical studies. Classified within the Q2 category in both Pharmacology and Psychiatry and Mental Health, it reflects a solid standing in academic performance, evidenced by its rankings in Scopus, where it places within the top half of its categories. Spanning from 1993 to 2024, it seeks to provide an essential platform for the dissemination of knowledge and advancements that influence clinical practice and therapeutic approaches. Although not an open-access journal, its impact on the development of evidence-based psychopharmacological treatments cannot be overstated, making it a vital resource for researchers, clinically active professionals, and students eager to stay abreast of cutting-edge developments in mental health and pharmacology.

PSYCHIATRY AND CLINICAL NEUROSCIENCES

Illuminating the Pathways of Mental Health Research
Publisher: WILEYISSN: 1323-1316Frequency: 12 issues/year

PSYCHIATRY AND CLINICAL NEUROSCIENCES is a leading journal in the fields of psychiatry and clinical neurology, published by Wiley. With a commendable impact factor and a position within the prestigious Q1 quartile across multiple relevant categories—including Medicine (Miscellaneous), Neurology, and Psychiatry and Mental Health—this journal stands out for its rigorous peer-reviewed content that addresses critical issues in mental health and neurological disorders. Established in 1933, the journal has a rich history of contributing impactful research that guides both clinical practice and academic inquiry. Although it is not an open-access journal, its high relevance is underscored by its Scopus rankings, with notable percentiles in Psychiatry and Neurology, making it a vital resource for researchers, clinicians, and students looking to stay abreast of the latest advancements. Located in the United Kingdom, PSYCHIATRY AND CLINICAL NEUROSCIENCES aims to bridge the gap between theory and practical application, fostering a comprehensive understanding of the complex interplay between mental health and neurological conditions.

BMJ Mental Health

Transforming mental health care through open access knowledge.
Publisher: BMJ PUBLISHING GROUPISSN: Frequency: 1 issue/year

BMJ Mental Health, published by the esteemed BMJ PUBLISHING GROUP, is a pioneering open-access journal dedicated to advancing research and knowledge in the field of Psychiatry and Mental Health. Launched in 2023, this journal has rapidly established itself within the academic community, achieving a prestigious Q1 ranking and a ranking of #123 out of 567 in its category, placing it in the 78th percentile according to Scopus. With its base in the United Kingdom, the journal aims to foster impactful research through its commitment to accessibility, allowing professionals, researchers, and students alike to engage with high-quality content freely. The E-ISSN: 2755-9734 enables seamless digital access to cutting-edge studies, reviews, and perspectives that address the complexities of mental health, thereby paving the way for better practices and innovations in mental health care. Join a community of dedicated scholars and practitioners in reshaping the landscape of mental health research with BMJ Mental Health.

PSYCHOPHARMACOLOGY

Fostering Multidisciplinary Dialogue in Psychopharmacology
Publisher: SPRINGERISSN: 0033-3158Frequency: 12 issues/year

PSYCHOPHARMACOLOGY is a leading peer-reviewed journal specializing in the field of pharmacology, specifically focusing on the effects of drugs on behavior, cognition, and emotion. Published by Springer, this esteemed journal has established itself as a pivotal resource for researchers and professionals since its inception in 1959, maintaining its relevance and rigor in the ever-evolving landscape of psychopharmacological research. With an impressive impact factor and ranking in the top quartile (Q1) of the Pharmacology category in 2023, it consistently publishes high-quality studies that contribute to both academic inquiry and clinical practice. The journal's scope includes original research, theoretical papers, and reviews, fostering a multidisciplinary dialogue among psychologists, psychiatrists, pharmacologists, and neuroscientists. As the field of psychopharmacology continues to grow, PSYCHOPHARMACOLOGY remains dedicated to disseminating innovative findings, operationalizing complex concepts, and enhancing the understanding of drug mechanisms and their implications for mental health. This commitment to excellence positions PSYCHOPHARMACOLOGY as an indispensable tool for those seeking to advance their knowledge and research in pharmacology.

Journal of Child and Adolescent Psychiatric Nursing

Fostering insights that enhance youth mental health outcomes.
Publisher: WILEYISSN: 1073-6077Frequency: 4 issues/year

Journal of Child and Adolescent Psychiatric Nursing is a vital resource for those engaged in the fields of nursing, psychiatry, and pediatrics, dedicated to the advance of knowledge surrounding the mental health needs of children and adolescents. Published by WILEY, this peer-reviewed journal, with ISSN 1073-6077 and E-ISSN 1744-6171, has built a reputation for excellence since its inception in 1988 and continues to contribute significant insights through 2024. The journal holds an impressive Q1 ranking in Pediatrics and a Q2 ranking in Medicine (miscellaneous), underscoring its impact within these critical areas. Enhancing its relevance, it ranks #12/25 in Nursing - Pediatrics and #17/45 in Nursing - Psychiatric Mental Health, highlighting its important niche. Although it currently does not offer open access, the journal remains essential for researchers, clinicians, and students focusing on the complexities of mental health nursing for younger populations, ultimately aiming to improve care strategies and outcomes. Discover compelling research and discussions that shape the future of psychiatric nursing practice, promoting the well-being of children and adolescents.

Journal of the Canadian Academy of Child and Adolescent Psychiatry

Exploring the intersection of pediatrics and mental health.
Publisher: CANADIAN ACAD CHILD & ADOLESCENT PSYCHIATRYISSN: 1719-8429Frequency: 4 issues/year

Journal of the Canadian Academy of Child and Adolescent Psychiatry, published by the esteemed Canadian Academy of Child & Adolescent Psychiatry, serves as a crucial platform for scholarly discourse in the fields of Pediatrics and Psychiatry. With an ISSN of 1719-8429, this journal has been significantly contributing to the advancement of knowledge from 2006 to 2024, achieving notable recognition as a Q2 journal in both Pediatrics, Perinatology and Child Health, and Psychiatry and Mental Health categories. The journal's current Scopus rankings reflect its quality, sitting at the 70th percentile in Pediatrics and the 55th percentile in Psychiatry. Though currently not an open access journal, it provides valuable insights, research findings, and clinical implications for researchers, clinicians, and students dedicated to child and adolescent mental health. Its location in Canada underscores a commitment to advancing healthcare and mental wellness for young populations through rigorous academic inquiry.

INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE

Advancing mental health knowledge for a brighter future.
Publisher: TAYLOR & FRANCIS LTDISSN: 1365-1501Frequency: 4 issues/year

INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE is a distinguished publication in the field of Psychiatry and Mental Health, published by TAYLOR & FRANCIS LTD in the United Kingdom. With an impressive 2023 impact factor that places it in the Q2 category among its peers, this journal is an essential resource for researchers, clinicians, and students dedicated to advancing mental health practices and understanding psychiatric disorders. Covering topics from clinical studies to innovative treatment methodologies, the journal welcomes original research, reviews, and case studies that contribute valuable insights into clinical practice. Accessible without any open access restrictions, the journal has been a pivotal platform since its inception in 1997, facilitating knowledge exchange in the field up to 2024. As evidenced by its notable Scopus ranking within the top 73rd percentile of Psychiatry and Mental Health, it remains committed to impacting clinical practices significantly.

World Psychiatry

Exploring Innovations in Psychiatric Science
Publisher: WILEYISSN: 1723-8617Frequency: 3 issues/year

World Psychiatry is a leading peer-reviewed journal dedicated to advancing the field of psychiatry and mental health. Published by WILEY and located in the United States, this esteemed journal boasts an impressive impact factor, ranking Q1 in the Psychiatry and Mental Health category for 2023. Recognized for its scholarly contributions, World Psychiatry ranks #1 out of 567 in the Scopus database for medicine in psychiatry and mental health, placing it in the top 1% of its field. The journal covers a wide scope of research topics, aiming to facilitate dialogue and innovation among researchers, professionals, and students alike. Though it does not offer open access, its comprehensive articles and analyses are accessible to a broad audience engaged in mental health studies. With converged years from 2007 to 2024, the journal continues to serve as a critical resource for the latest advancements and evidence-based practices in psychiatry.

JOURNAL OF PSYCHOPHARMACOLOGY

Unraveling the Complexities of Mind-Altering Substances
Publisher: SAGE PUBLICATIONS LTDISSN: 0269-8811Frequency: 12 issues/year

JOURNAL OF PSYCHOPHARMACOLOGY, published by SAGE Publications Ltd, is a leading peer-reviewed journal that explores the intricate dynamics of pharmacological interventions in mental health and psychiatry. With an ISSN of 0269-8811 and an E-ISSN of 1461-7285, this esteemed journal has established its reputation in the field since its inception in 1987, converging research excellence into 2024. Recognized as a Q1 journal in various categories including Medicine (miscellaneous), Pharmacology, and Psychiatry and Mental Health, it ranks impressively within the top percentile in Scopus, standing at #64 out of 567 in Psychiatry and Mental Health, and #31 out of 272 in Medical Pharmacology. The journal serves as a vital resource for researchers, professionals, and students, providing insightful articles that advance the understanding of psychopharmacological effects and innovations. Although it does not offer open access, the journal's extensive research and impactful findings make it essential reading for anyone engaged in the field. For those seeking to stay at the forefront of psychopharmacology, the JOURNAL OF PSYCHOPHARMACOLOGY is an invaluable asset.